Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

mucocutaneous lymph node syndrome - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

mucocutaneous lymph node syndrome

MONDO:0012727

Also known as:Kawasaki's diseaseMLNSacute febrile MCLS

Find Clinical TrialsTrials

Overview

Kawasaki disease (KD) is a febrile, systemic, self-limiting vasculitis affecting children and characterized by inflammation in the medium sized vessels associated with coronary arterial aneurysms (CAA) that may be life threatening when untreated. KD is the most common cause of acquired heart disease in children in developed countries and is a risk factor for ischemic heart disease in adulthood.

TreatmentsNo approved treatments · 3 in pipeline

Clinical Trials19 registered · 11 recruiting

Diagnosis

Biomarker and diagnostic research for mucocutaneous lymph node syndrome has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for mucocutaneous lymph node syndrome. An additional 3 compounds hold orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for mucocutaneous lymph node syndrome, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for mucocutaneous lymph node syndrome. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

19 clinical trials registered, 11 recruiting. Interventions under study include other interventions and drug therapy. Pipeline includes 3 PHASE4, 3 PHASE3, 2 PHASE2. Research is primarily sponsored by academic and government institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT04278404](https://clinicaltrials.gov/study/NCT04278404)

Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 7:06 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

OMIM

Online Mendelian Inheritance in Man

OMIM:611775

Orphanet

European rare disease database

Orphanet:2331

GARD

Genetic and Rare Diseases Info Center

GARD:6816

Questions for Your Care Team

→Are any of the 19 active clinical trials a good fit for my situation?
→With 3 compounds in the orphan drug pipeline, which are furthest along in development and which clinical trials should I be aware of?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Research summaries	12	41%
Laboratory research	5	17%
Patient case studies	4	14%
Disease patterns and progression	4	14%
Testing and diagnosis research	3	10%
Clinical study results	1	3%

mucocutaneous lymph node syndrome

Overview

Diagnosis

Treatment

Orphan Drug Designations

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications